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Objectives: To present prospective aggregated data
of an off-the-shelf (OTS) fenestrated endograft
(Zenith p-Branch) from 4 centers for the treatment
of patients with juxtarenal or pararenal abdominal aortic
aneurysms.
Methods: The p-Branch endograft consists of a
proximal, OTS component incorporating a scallop for the
celiac artery, a superior mesenteric artery (SMA) fenestra-
tion, and two conical-shaped pivot fenestrations to preserve
ﬂow to the renal vessels. The device is available in two con-
ﬁgurations; a left renal fenestration at the same (A) or lower
(B) longitudinal position than the right renal fenestration,
to accommodate varied patient anatomies. One-year results
with a data cutoff of November 21, 2013 are presented.
Results: Of 54 patients (81% male; mean age, 72
years; 47 elective and seven emergent) enrolled, 57%
were implanted with option A, and 43% with B. The device
was deployed successfully in all patients and stents placed in
all target vessels except in two emergent cases: a left kidney
was sacriﬁced in one patient and a right renal artery was
unstented in one patient during the index procedure.
There were no deaths, ruptures, or conversions to open
repair. One emergent patient had a site-reported type I
endoleak; no other type I/III endoleaks were observed.
One patient experienced bowel ischemia that resolved
with nonoperative treatment. Renal artery occlusion/se-
vere stenosis occurred in six patients (11%) deemed proce-
dure-related by the implanting physician in 83% of the
patients. Four (67%) of these were successfully intervened
upon with preservation of renal function. The overall renal
insufﬁciency incidence was 4%. No patient developed renal
failure requiring dialysis.
Conclusions: Early results incorporating physician
learning curves with a new device and delivery system indi-
cate that the use of the Zenith p-Branch device is feasible
and safe. Long-term follow-up is needed to assess the effec-
tiveness and durability of this treatment strategy and reﬁne
the indications for use.
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Objectives: To describe the 1 year (yr) results of the
Terumo Anaconda ONE-LOK Stent Graft System Phase
II IDE Study for the treatment of infrarenal abdominal
aortic aneurysm (AAA)
Methods: This Investigational Device Exemption
(IDE) trial enrolled 195 patients at 23 sites in the US
and Canada between June 2009 and May 2012. Outcomes
were compared with the historical open surgical controls
from the Society for Vascular Surgery (SVS) registry.
Chi-squared analysis, Fishers exact test and Kaplan-Meier
analysis were performed.
Results: The primary safety endpoint was met with
95.9% freedom from major adverse events (MAE) at 30
days deﬁned as all-cause mortality, myocardial infarction
(MI), renal failure (RenF), respiratory failure (RespF),
paralysis or paraplegia, cerebrovascular accident, and
bowel ischemia. There was 1 nonaneurysm-related mor-
tality, 5 MI, and 2 patients with RespF. Secondary safety
end points include incidence of MAEs at 1 yr and
freedom from abdominal aortic aneurysm (AAA) related
mortality at # 30 and # 365 days. There was no AAA
rupture or AAA-related mortality with 1 yr all-cause mor-
tality of 3.1% (six patients). Other MAEs were 7 MI
(3.6%), 2 RenF (1.0%), and 2 RespF (1.0%). Technical
success through the ﬁrst 24 hrs was 96.9%. Primary efﬁ-
cacy of EVAR at 1 yr was 93%. 96.4% of patients experi-
enced aneurysm sac shrinkage or stabilization at 1 yr.
Limb occlusions occurred in seven patients (3.6%) at 1
yr. Five (2.6%) type I endoleaks were treated; no Type
III endoleaks were treated. 3.6% percent of pts had
type II endoleaks requiring treatment. Freedom from
secondary interventions was 99.5% at 30 days and
95.1% at 1 yr.
Conclusions: EVAR performed using the Terumo
Anaconda OneeLok stent graft system is safe and effective
at preventing AAA related death when compared with
open repair, with minimal need for reintervention at 1 yr.
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